A one-time gene therapy treatment has shown remarkable success in slowing the progression of Huntington's disease in a preliminary trial, according to a press release from University College London (UCL). The experimental treatment, called AMT-130, reduced disease progression by 75% over three years in patients who received a high dose, compared to those on standard care, according to researchers. While these early results are promising, they are preliminary and the treatment could still years away from potential FDA approval, with the earliest application expected in 2026. "This result changes everything," UCL professor Ed Wild said in the press release. "One of my patients who had to retire due to the disease has even been able to return to work." Huntington's disease affects about 100,0

See Full Page